Skip to main content
رجوع
Watch Compare

Kalaris Therapeutics, Inc.

جودة البيانات: 83%
KLRS
NASDAQ Manufacturing Chemicals
KWD 5.87
▲ KWD 0.05 (0.86%)
6 months return
—
Momentum
Neutral
ROE
-91.47%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-91.47%
أقل من متوسط القطاع (-54.47%)
ROIC-45.49%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio12.89
Interest Coverage-31.98

التقييم

PE (TTM|NTM)
-3.16 | -4.33
أقل من متوسط القطاع (-1.49)
P/B Ratio3.28
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -38.57 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

6 محللين
Buy
+246.4%
upside to target
الحالي
KWD 5.87
Consensus Target
KWD 20.33
KWD 7.00
أدنى
KWD 27.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-4.33
ربحية السهم المستقبلية
-KWD 1.45
الإيرادات المقدّرة
13.33 M

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.53 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 2.52 -KWD 0.61 -KWD 0.64 -KWD 0.44 — —
Estimate -KWD 0.78 -KWD 0.52 -KWD 0.61 -KWD 0.55 -KWD 0.53 -KWD 0.55
المفاجأة -225.16% -17.31% -4.49% +20.00% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -91.47% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -43.44 M
ROE -91.47% ROA -49.92%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -38.57 M
ROIC -45.49% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 12.89
Debt / Equity N/A Current Ratio 12.89
Interest Coverage -31.98 Asset Turnover N/A
Working Capital 72.12 M Tangible Book Value 41.87 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -3.16 · EV/EBITDA: N/A
P/E Ratio -3.16 Forward P/E -4.33
P/B Ratio 3.28 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 10.30 Fwd Earnings Yield N/A
FCF Yield -28.08%
Market Cap 137.34 M Enterprise Value 94.95 M

Per Share

EPS: -2.85 · FCF/Share: -1.68
EPS (Diluted TTM) -2.85 Revenue / Share N/A
FCF / Share -1.68 OCF / Share -1.67
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 88.79% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 88.79%
SBC-Adj. FCF -45.12 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -43.44 M -58.77 M -190.42 M -168.71 M -171.96 M
EPS (Diluted) -2.85 -11.73 -1.83 -2.20 —
Gross Profit — — — — —
Operating Income -46.15 M -65.44 M -199.90 M -171.20 M -169.82 M
EBITDA — — — — —
R&D Expenses 30.75 M 12.34 M 133.07 M 118.87 M 120.74 M
SG&A Expenses — — — — —
D&A — 398,000.0 398,000.0 723,000.0 189,000.0
Interest Expense 1.44 M — — — —
Income Tax 0.0 0.0 -126,000.0 -265,000.0 1.01 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 121.74 M 118.55 M 190.80 M 277.08 M 286.59 M
Total Liabilities 42.92 M 5.24 M 45.02 M 52.56 M 61.33 M
Shareholders' Equity 78.81 M 113.31 M 145.78 M 224.52 M 225.27 M
Total Debt — — — — —
Cash & Equivalents 98.05 M 118.29 M 90.12 M 106.09 M 201.66 M
Current Assets 118.81 M 118.55 M 187.64 M 243.05 M 253.35 M
Current Liabilities 9.71 M 5.24 M 28.37 M 24.34 M 37.85 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -3.2 -1.5
P/B 3.3 1.6
ROE % -91.5 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3